| Entries |
| Document | Title | Date |
|---|
| 20090018209 | CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS - Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis. | 01-15-2009 |
| 20090042995 | THERAPEUTIC FORMULATION - A pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and, optionally, an acetogenin. The formulation demonstrates positive effects against cancer, autoimmune disease, viruses and provides antioxidant protection against peroxyl, hydroxyl and super oxide radicals. | 02-12-2009 |
| 20090275665 | Enhanced biological potential of greater than 99% pure form of 1, 7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione over corresponding 95% pure form-therapeutic and agricultural applications thereof - Disclosed are novel and enhanced anti-fungal properties of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione in comparison with the corresponding 95% pure form, said greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione being devoid of 5-Hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone and 3,5-Dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-heptane. The inventors disclose the uses of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione as anti-fungal agents capable of inhibiting superficial and cutaneous mycoses in humans and treatment methods thereof. Also disclosed is the enhanced potential of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione as compared to the corresponding 95% pure form against bacterial and fungal phytopathogens and applications thereof in agriculture. | 11-05-2009 |
| 20090318565 | Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof - Disclosed are novel compositions for the enhancement of the anti-oxidant potential of natural or metabolite hydrogenated (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione derivatives. It was discovered that the antioxidant potential of hydrogenated curcuminoids was highly enhanced when a closely structurally related 1,7-Bis(4-hydroxyphenyl)-3,5-heptanedione, exhibiting unexpectedly pro-oxidant properties, was removed from the compositions. | 12-24-2009 |
| 20100048727 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF - Novel perfluoroketone compounds of formula [I] and [Ia] are described. Also described are uses thereof, such as for inhibition of phospholipase A | 02-25-2010 |
| 20100168248 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA - A process for producing an enriched fraction of tetrahydoxycurcumin containing, tetrahydroxycurcumin, demethylcurcumin, demethylmonodemethoxycurcumin and bisd.emethoxycurcumin and colorless tetrahydroderivatives thereof. The process consists of demethylation of natural curcumins, obtained, in turn, from the organic solvent extract of turmeric from | 07-01-2010 |
| 20100190862 | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient - The present invention relates to a composition for treating atopic dermatitis comprising hirsutenone as an active ingredient. Hirsutenone as the active ingredient of the present composition decreases the number of eosinophil and the level of IgE increased in atopic dermatitis and remarkably reduces expression amounts of immune regulatory cytokine (e.g., IL-4, IL-5 and IL-13) associated with atopic dermatitis. In addition, hirsutenone decreases COX-2 and iNOS expression. Hirsutenone as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis or relieving a symptom of atopic dermatitis. | 07-29-2010 |
| 20100292342 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof - The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver cancer, breast cancer and Kennedy's disease. | 11-18-2010 |
| 20100298444 | Method for improving the therapeutic efficacy of curcuminoids and their analogs - The invention relates to a method for increasing the therapeutic efficacy of curcuminoids and analogs. More specifically, the invention relates to a method for increasing the therapeutic efficacy of systemically administered formulations that contain curcuminoids and the equivalent therapeutics thereof. The method is characterized in that together with the administration of the formulation the patient is irradiated with visible, and optionally ultraviolet, radiation during a treatment. The invention also relates to phototherapy devices that emit visible radiation over a surface area greater than 0.2 m | 11-25-2010 |
| 20110021637 | XANTHOHUMOL AND TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT - Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops. | 01-27-2011 |
| 20110034564 | SOLUBLE COMPLEXES OF CURCUMIN - A composition comprising a water-soluble and stable complex formed by an alkyl ether derivative of gamma-cyclodextrin and curcumin and optionally comprising non-complexed cyclodextrin, the molar ratio of curcumin to cyclodextrin being between 1:1 and 1:6, and a method of manufacturing such a composition. The water-soluble and stable complex of curcumin is useful in therapy, e.g. for treatment of cancer, leukemia, myocardial infarction, stroke, sepsis, acute lung injury, acute liver failure, acute tubular necrosis, acute pancreatitis, radiation injury and other life-threatening conditions in a human or animal subject, as well as for preserving human or animal organs, tissues or cells at a hypothermic temperature. | 02-10-2011 |
| 20110092603 | Composition to enhance the bioavailability of curcumin - A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared to bioavailability of curcumin obtained upon administration of a composition prepared without adding essential oil to the curcuminoid. A method to prepare a composition having a curcuminoid and an essential oil of turmeric. | 04-21-2011 |
| 20110098361 | Composition to enhance the bioavailability of curcumin - A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric. | 04-28-2011 |
| 20110124740 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF - The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition containing the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compound has an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases. | 05-26-2011 |
| 20110152382 | Composition of molecular elements for phosphorylase kinase inhibition - Symmetrical curcuminoids molecular compounds that have been found to have anti-injury activity. It has been shown to benefit burns, injured and inflamed skin and mucous membrane and photodamaged skin. The improvement is mediated via inhibition of phosphorylase kinase activity. Phosphorylase kinase is released within 5 minutes following injury. Blocking the elevated phosphorylase kinase activity released after injury by phosphorylase kinase inhibitors, such as symmetrical curcuminoids, results in rapid reversal of burns, skin and mucous membrane injury and inflammation, repair of photodamaged skin, and prevention of scar tissue formation after injury. | 06-23-2011 |
| 20110190399 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME - The present invention provides for curcumin nanoparticles and curcumin bound to chitosan nanoparticles and methods of producing the same. Bioavailability of curcumin in these formulations was shown to improve by more than 10 fold. | 08-04-2011 |
| 20110196044 | PRODUCTION OF ORGANIC COMPOUND NANOPARTICLES WITH HIGH REPETITION RATE ULTRAFAST PULSED LASER ABLATION IN LIQUIDS - Disclosed is a method of producing a chemically pure and stably dispersed organic nanoparticle colloidal suspension using an ultrafast pulsed laser ablation process. The method comprises irradiating a target of an organic compound material in contact with a poor solvent with ultrashort laser pulses at a high repetition rate and collecting the nanoparticles of the organic compound produced. The method may be implemented with a high repetition rate ultrafast pulsed laser source, an optical system for focusing and moving the pulsed laser beam, an organic compound target in contact with a poor solvent, and a solvent circulating system to cool the laser focal volume and collect the produced nanoparticle products. By controlling various laser parameters, and with optional poor solvent flow movement, the method provides stable colloids of dispersed organic nanoparticles in the poor solvent in the absence of any stabilizing agents. | 08-11-2011 |
| 20110257271 | DERIVATIVES OF DIMETHYLCURCUMIN - The invention relates to compounds of Formula I or Ia as disclosed herein: | 10-20-2011 |
| 20110294900 | SELF EMULSIFYING DRUG DELIVERY SYSTEM FOR A CURCUMINOID BASED COMPOSITION - The present invention discloses a pharmaceutical composition in the form of self nano emulsifying drug delivery formulation comprising curcuminoids. The pharmaceutical composition of the present invention shows an enhanced drug loading ability, better stability and an improved bioavailability. The composition of the present invention comprises of a pharmaceutically effective amount of a curcuminoid, an oil phase, a surfactant and a co surfactant. | 12-01-2011 |
| 20120129948 | MEDICAL IMPLANT PRODUCING WEAR PARTICLES WITH BENIGN BODY RESPONSE - A substance, which contains anti-inflammatory substances, anti-microbial substances, anti-tumor substances, anti-viral substances, and/or bone stimulating substances, as an additive, can be added to an UHMWPE material for the production of a medical implant for imparting benign body response properties to the medical implant. | 05-24-2012 |
| 20120220666 | Composition to enhance the bioavailability of curcumin - A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared to bioavailability of curcumin obtained upon administration of a composition prepared without adding essential oil to the curcuminoid. A method to prepare a composition having a curcuminoid and an essential oil of turmeric. | 08-30-2012 |
| 20130005824 | TREATMENT OF ISCHEMIC TISSUE - The present invention features methods of treating patient for ischemic tissue damage. The methods can be carried out by administering (e.g., intravenously administering) a curcuminoid or a pharmaceutically active salt, metabolite, or analog thereof at low doses. | 01-03-2013 |
| 20130116335 | METHOD FOR IDENTIFYING THERAPEUTIC AGENTS FOR TREATMENT OF CANCER - The presence of phosphorylated Cdc27 in cancer cells is utilized to identify patients likely to benefit from treatment with a chemotherapeutic agent that binds to, or binds to and crosslinks, phosphorylated Cdc27, e.g., curcumin, or to determine whether patients undergoing such treatment will continue to respond effectively. Candidate compounds are screened for anticancer effect by testing the ability to bind to or crosslink phosphorylated Cdc27. | 05-09-2013 |
| 20130143969 | CURCUMIN COMPOSITIONS AND USES THEREOF - A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer. | 06-06-2013 |
| 20130225689 | PHARMACEUTICAL COMPOSITIONS OF CURCUMIN - The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition. | 08-29-2013 |
| 20130237609 | CELLULOSE DERIVATIVES FOR ENHANCING BIOAVAILABILITY OF FLAVONOIDS - The present invention relates to delivery systems to enhance the bioavailability of flavonoids to improve human health. Flavonoids of interest include but are not limited to curcumin, resveratrol, ellagic acid, naringenin, and quercetin. Flavonoids are important in part because they are known to have beneficial effects on human health, including cardioprotective, antioxidant, and anticancer effects. Utility has been limited by low bioavailability, both in the sense of requiring high doses and in that it has been difficult to carry out proper dose-response studies in the absence of methods to control the actual dose administered. In addition to pharmaceutical applications, there are potential nutraceutical uses, for example in supplements that might be sold in health food stores and pharmacies. | 09-12-2013 |
| 20130245128 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE - The use of 3,4,3′,4′-tetrahydroxychalcone in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease. | 09-19-2013 |
| 20130274343 | Water Soluble Composition Comprising Curcumin Having Enhanced Bioavailability and Process Thereof - The invention disclosed relates to a water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises a synergistic combination of curcumin, at least an antioxidant, a hydrophilic carrier and a fat. The invention also discloses a process for the preparation of the curcumin composition which comprises the steps of dissolving curcumin, at least one antioxidant, a hydrophilic carrier and a fat in a solvent to form a homogenous mass; warming the resultant mass at a temperature ranging from 25° C. to 60° C. for a period of 4 to 8 hours to obtain a dry wet mass; removing the solvent by evaporation to form dry mass and pulverizing the dry mass to form a fine powder. | 10-17-2013 |
| 20130296440 | PTEROSTILBENE AND CURCUMIN COMBINATION FOR TREATMENT OF OXIDATIVE STRESS AND INFLAMMATION - A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier. The combination containing pterostilbene and curcumin is effective for treatment or prevention of oxidative stress, treatment of digestive disorders including inflammatory bowel disease, and/or to reduce or inhibit inflammation, in both animals and in humans. | 11-07-2013 |
| 20130303628 | CURCUMINOID SOLID DISPERSION FORMULATION - A curcuminoid formulation, comprising a melt-processed solid dispersion product comprising one or more curcuminoids, a nutritionally acceptable thermoplastic polymer, and a phosphatide; providing an improved oral bioavailability compared to non-formulated crystalline curcuminoid. A method for producing said formulation. A nutritional product fortified with said formulation. Said formulation for use in the treatment or prophylaxis of cancer, conditions involving an inflammatory reaction, neurological disorders, cardiovascular disease, pulmonary disease, the formation of cholesterol gallstones, and parasitic infestation. | 11-14-2013 |
| 20130317116 | EXTERNAL SKIN PREPARATION - This invention provides an external skin preparation with high safety aimed at wrinkle improvement and wrinkle prevention. Specifically, the invention relates to an external skin preparation comprising, as an active ingredient, a carotenoid. | 11-28-2013 |
| 20130338233 | METHODS FOR MICROBIAL BIOFILM DESTRUCTION - Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises | 12-19-2013 |
| 20140088200 | Composition to Enhance the Bioavailability of Curcumin - A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric. | 03-27-2014 |
| 20140275283 | Product and Method for Improving Bioavailability of Therapeutic Compounds - Disclosed is a method for improving the bioavailability of a variety of compounds such as phenolic acids, polyphenols, hydroxyl-cinnamic acids, curcumin, curcumin analogs, curcuminoids, etc., using milk protein concentrate and/or similar milk protein products. | 09-18-2014 |
| 20140303258 | Method of solubilizing insoluble bioactive compounds using triterpene glycosides and compositions thereof - Disclosed are the uses of triterpene glycosides as non-toxic natural solubilizing agents for bioactive compounds and/or metabolites thereof. Triterpene glycosides are also shown to solubilize insoluble natural extracts. Also disclosed are exemplary methods and compositions incorporating the uses of triterpene glycosides as non-toxic natural solubilizing agents. | 10-09-2014 |
| 20140371326 | FOOD COMPOSITION FOR PREVENTING OBESITY, PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY, AND ANIMAL MEDICINE FOR TREATING OBESITY, CONTAINING GINGERNONE A - Disclosed is a composition comprising gingerenone A as an active ingredient. The composition includes a food composition for preventing obesity, a pharmaceutical composition for treating obesity and a medicine for treating animal obesity. Since the composition includes gingerenone A, which inhibits expression of the important transcriptional factors C/EBPα and PPARγ, expressed upon adipocyte differentiation, as well as FAS protein expression, the composition has superior potential for obesity prevention or treatment. | 12-18-2014 |
| 20140371327 | Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof - Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided. | 12-18-2014 |
| 20150057362 | Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition - The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer. | 02-26-2015 |
| 20150297536 | CURCUMIN COMPOSITIONS AND USES THEREOF - Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic methods using conventional equipments and can be effectively used for enhancing muscle and exercise performance. | 10-22-2015 |
| 20150342904 | PHARMACEUTICAL COMPOSITION CONTAINING CURCUMIN - The subject matter of the invention is a pharmaceutical formulation which, according to the invention, contains curcumin or a curcumin derivative dissolved in an alcohol, an acid and an solubiliser. The formulation contains at most 12 percent by weight water and makes possible the production of an aqueous infusion solution, by means of which curcumin can be administered intravenously in dissolved form. | 12-03-2015 |
| 20160008479 | Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof | 01-14-2016 |
| 20160022605 | METHODS FOR REDUCING MICROSATELLITE INSTABILITY INDUCED BY CHEMOTHERAPY AND METHODS FOR SCREENING ANTIOXIDANTS THAT SUPPRESS DRUG-INDUCED MICROSATELLITE INSTABILITY WHILE ENHANCING THE CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS - A therapeutic approach to prevent drug resistance and chemotherapy-related secondary cancer associated with DNA mismatch repair (MMR) deficiency is disclosed based on screening antioxidants for reducing microsatellite instability (MSI) while enhancing the cytotoxicity of chemotherapeutic agents. The work is based on experiments using antioxidants to target reactive oxygen species generated by oxaliplatin, a commonly used chemotherapeutic agent, and is applicable to other chemotherapeutic agent, and in particular 5-fluorouracil, methotrexate, CCNU, etoposide and vinblastine. In particular oxaliplatin is co-treated with an antioxidant, including CDC, CAPE, ciclopirox ethanolamine, hinokitiol, gossypol, n-Octyl caffeate, baicalein, or curcumin. | 01-28-2016 |
| 20160074338 | FOOD COMPOSITION FOR PREVENTING OBESITY, PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY, AND ANIMAL MEDICINE FOR TREATING OBESITY, CONTAINING GINGERNONE A - Disclosed is a composition comprising gingerenone A as an active ingredient. The composition includes a food composition for preventing obesity, a pharmaceutical composition for treating obesity and a medicine for treating animal obesity. Since the composition includes gingerenone A, which inhibits expression of the important transcriptional factors C/EBPα and PPARγ, expressed upon adipocyte differentiation, as well as FAS protein expression, the composition has superior potential for obesity prevention or treatment. | 03-17-2016 |
| 20160089343 | MICROSIZED CURCUMIN COMPOSITIONS - Disclosed herein are formulations for the local delivery of therapeutically effective doses of curcumin that provide sufficient serum levels of curcumin to treat diseases such as head and neck disorders and upper aerodigestive disorders. | 03-31-2016 |
| 20160106687 | HUMAN THERAPEUTIC AGENTS - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 04-21-2016 |
| 20160166516 | NOVEL CURCUMINOID FORMULATIONS AND RELATED METHODS OF TREATMENT | 06-16-2016 |
| 20160166699 | Oral Composition for Delivery of Drugs and Other Substances | 06-16-2016 |
